Skip to main content
Natera

Built for the Future

of oncology drug development

Build with us.

Meet with us

Unsurpassed MRD technology detects the signals that can change the trajectory of cancer.

Natera conducts

97%

of all commercial solid-tumor MRD testing1

Natera technology powers

90%

of MRD peer-reviewed publications2

Why does Phased Variant Technology really matter?
More signal. Less noise.

Single Nucleotide Variant (SNV)-only

1 SNV detected

DNA sequencing read showing one SNV variant highlighted among many base pairs

Probability of error detecting an SNV is

1/10,0003

Phased Variants

2+ SNVs co-occurring on the same DNA molecule

DNA sequencing read showing two co-occurring phased variants highlighted on the same molecule

Probability of error detecting a PV (2+ SNVs) is

~1/100,000,0003

Exclusive Phased Variant Technology improves confidence across tracked variants, enabling market-leading detection down to 0.1 PPM4

Ultra-Sensitive meets Ultra-Smart: Natera has the only MRD assays with error-reducing, sensitivity-boosting Phased Variant technology.5

A validated platform built to scale with the most impactful programs in oncology.

Molecular Residual Disease Assays

Signatera™ Genome

TIssue-Informed Ultra-sensitive MRD

Ultra-Sensitive Meets Ultra-Smart

The only ultrasensitive MRD assay that tracks PV, SV, and SNVs — for the highest fidelity signal with detection below 1 PPM.6,7

Latitude™ PanTumor

Tissue-free MRD

Built for speed & efficiency

A rapid & sensitive methylation-based ctDNA MRD assay for treatment response monitoring in metastatic settings and as a reflex to Signatera™ when tissue is unavailable.8

Clarity™

Tumor-Informed High-plex MRD

Hybrid capture assay for variant tracking

Ultra-sensitive MRD assay that tracks up to 5,000 PVs & SNVs for solid tumors – also available as a fixed plasma-informed assay in lymphoma9

Our Partnership Model

Real World Molecular Intelligence & AI

  • Leverage Natera's clinical scale that drives continuous data generation
  • MRD data connected to real world data at each testing timepoint (~ 5 tests / pt)7

Trial Design & Patient Identification

  • Convert the largest clinical testing footprint into real-time trial enrollment with feasibility testing, site selection, and real-time patient matching

Signatera™ detects relapse up to 10.5 months before imaging

Colon10,11

JAMA Oncology

Colon relapse-free survival Kaplan–Meier curve showing ctDNA positive vs. negative groups

8.7 mos

Median lead time

Breast12,13

Clinical Cancer Research

Breast relapse-free survival Kaplan–Meier curve showing ctDNA positive vs. negative groups

10.5 mos

Median lead time

Lung14,15

Frontiers in Oncology

Lung relapse-free survival Kaplan–Meier curve showing ctDNA positive vs. negative groups

5.4 mos

Median lead time

Bladder16

Journal of Clin Oncology

Bladder relapse-free survival Kaplan–Meier curve showing ctDNA positive vs. negative groups

2.8 mos

Median lead time

Ovarian17

Gynecologic Oncology

Ovarian relapse-free survival Kaplan–Meier curve showing ctDNA positive vs. negative groups

10 mos

Avg lead time

Identify high-risk MRD patients who could benefit from novel treatment options earlier

Join us in building the future

From enrichment to response monitoring, Natera is experienced with MRD-powered trial design at every phase of development.

IMvigor011

Approved1st FDA-approved MRD CDx

CIRCULATE-Japan

Phase 3

CIRCULATE-France

Phase 3

CIRCULATE-NA (NRG-GI008)

Phase 3

SAGITTARIUS

Phase 3

STELLAR-316

Phase 3

EORTC Treat ctDNA

Phase 3

Archer (NRG)

Phase 3

MODERN (Alliance)

Phase 3

M24-534

Phase 2

EMPIRE (NSABP)

Phase 2

DECIPHER

Phase 2

TRINITY

Phase 2

I-SPY 2

Phase 2

LEADER

Phase 2

DARE

Phase 2

SAFE-de

Phase 2

SIGNAL-ER 101

Phase 2

MONSTAR-ov

Phase 2

BESPOKE

Phase 1Obs.

Latest Updates

FDA Approved

The first and only CDx Approval

Signatera™ CDx is the first and only FDA-approved MRD Companion Diagnostic based on IMvigor011, in partnership with Genentech, a member of the Roche Group. Signatera-positive patients treated with atezolizumab saw a 55% median improvement in overall survival (OS).18

ALPHA3

ALPHA3 in partnership with Allogene

Positive ALPHA3 interim analysis supports MRD-guided intervention in LBCL

We believe innovative and accurate diagnostics lead to life-changing cancer care.

Guided by science and a shared commitment to patients, we serve as a trusted partner to biopharma across every stage of drug development.

Partner With Us

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

*Indicates required field